key articles
Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia
Thursday, 7 August 2008 - Neuhouser et al. (2008) investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor...
Authors: Neuhouser et al.
Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer
Thursday, 7 August 2008 - Preclinical evidence supports the role of estrogen receptor signaling in prostate cancer. Chadha et al. (2008) investigated the tolerability and efficacy of fulvestrant, a pure estrogen receptor...
Authors: Chadha et al.
Survival following primary androgen deprivation therapy among men with localized prostate cancer
Wednesday, 6 August 2008 - Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of...
Authors: Lu-Yao et al.
Robotic laparoscopic radical prostatectomy for biopsy Gleason 8 to 10
Wednesday, 6 August 2008 - Shikanov et al. (2008) evaluated the pathologic results and postoperative outcomes for men undergoing robot-assisted laparoscopic radical prostatectomy (RLRP) for biopsy Gleason score (GS) 8 to 10...
Authors: Shikanov et al.
Laparoscopic port-site metastasis in urologic surgery
Tuesday, 5 August 2008 - Port-site metastasis has been an increasing concern with the spread of laparoscopy in managing urologic malignancies. Eng et al. (2008) reviewed port-site metastases reported in the urologic oncology...
Authors: Eng et al.
Impact of obesity on clinicopathologic outcomes after robot-assisted laparoscopic prostatectomy
Tuesday, 5 August 2008 - Boorjian et al. (2008) investigated the impact of body mass index (BMI) on pathologic and functional outcomes after robot-assisted laparoscopic prostatectomy (RALP).
The authors evaluated 400 consecutive...
Authors: Boorjian et al.
A new fiducial marker for image guided radio therapy of prostate cancer
Monday, 4 August 2008 - A new fiducial marker for image guided radiotherapy (IGRT) based on a removable prostate stent made of Ni Ti has been developed during two previous clinical feasibility studies. Carl et al. (2008)...
Authors: Carl et al.
Effect of serial prostate-specific antigen screening and its velocity on prostate cancer specific mortality
Monday, 4 August 2008 - A prostate-specific antigen (PSA) velocity (PSAV) > 2 ng/mL during the year before diagnosis has been associated with an increased risk of prostate cancer-specific mortality (PCSM) after radical...
Authors: Martin et al.
Informed decision-making for prostate-specific antigen screening
Monday, 4 August 2008 - Most medical associations recommend that patients make informed decisions about whether to be screened for prostate cancer with the prostate-specific antigen (PSA) test. Studies assessing how to...
Authors: Driscoll et al.
Doubling time versus velocity of prostate specific antigen to predict high-risk prostate cancer
Sunday, 3 August 2008 - Prostate-specific antigen (PSA) velocity (PSAV) is associated with the presence of life-threatening prostate cancer. Less is known about the relative utility of pretreatment PSA doubling time (PSA DT) to...
Authors: Loeb et al.
